Liu Yalan, Chen Peng, Liu Xinfu
Department of Oncology, The Central Hospital of Shaoyang, Shaoyang 422000, China.
Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin 300060, China.
Zhongguo Fei Ai Za Zhi. 2024 Nov 20;27(11):878-884. doi: 10.3779/j.issn.1009-3419.2024.106.32.
With the rapid development of epidermal growth factor receptor (EGFR) gene testing of lung adenocarcinoma patients has been routinely carried out, EGFR mutations are also possible for some small samples of non-smoking female lung squamous cell carcinoma patients. This increases the opportunity for targeted therapy for this group of patients. However, drug resistance in patients with lung squamous cell carcinoma during targeted therapy is an important factor affecting subsequent treatment. There are multiple mechanisms of acquired drug resistance in targeted therapy, and the alteration of mesenchymal-epithelial transition factor (MET) signaling pathway is one of the common mechanisms of drug resistance. At present, some selective tyrosine kinase inhibitors (TKIs) of MET has been approved for non-small cell lung cancer with MET gene 14 exon skipping mutation, such as Glumetinib, Savolitinib, Tepotinib, Capmatinib, etc. Drugs that target secondary MET amplification are still in clinical trials. This paper retrospectively analyzed the clinical data of a female patient with EGFR-TKIs resistant secondary MET amplified squamous cell lung cancer, and reviewed relevant literature to explore how to optimize the treatment of lung squamous cell carcinoma patients with EGFR mutation, so as to provide clinical reference for the diagnosis and treatment of such patients. .
随着肺腺癌患者表皮生长因子受体（EGFR）基因检测的迅速开展并已常规进行，一些非吸烟女性肺鳞癌小样本患者也可能存在EGFR突变。这增加了该组患者接受靶向治疗的机会。然而，肺鳞癌患者在靶向治疗过程中的耐药性是影响后续治疗的重要因素。靶向治疗中获得性耐药有多种机制，间充质上皮转化因子（MET）信号通路改变是常见的耐药机制之一。目前，一些MET选择性酪氨酸激酶抑制剂（TKIs）已被批准用于治疗具有MET基因第14外显子跳跃突变的非小细胞肺癌，如谷美替尼、赛沃替尼、替泊替尼、卡马替尼等。针对继发性MET扩增的药物仍在临床试验中。本文回顾性分析了1例EGFR-TKIs耐药继发性MET扩增的肺鳞癌女性患者的临床资料，并复习相关文献，探讨如何优化EGFR突变肺鳞癌患者的治疗，为这类患者的诊治提供临床参考。
